Targeted radioimmunotherapy: The role of 131I-chTNT-1/B mAb (Cotara®) for treatment of high-grade gliomas

Future Oncology

Volumn 8, Issue 6, 2012, Pages 659-669

  Hdeib, Alia ^a   Sloan, Andrew ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

131I chTNT 1 B mAb; Cotara ; high grade glioma; malignant glioma; radioimmunotherapy; tumor necrosis therapy

Indexed keywords

ASTATINE; CHIMERIC ANTIBODY; COTARA; EPITOPE; FIBRONECTIN; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; TENASCIN ANTIBODY; UNCLASSIFIED DRUG;

ALOPECIA; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; APHASIA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN EDEMA; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; COGNITIVE DEFECT; COLORECTAL CANCER; CONVECTION ENHANCED DELIVERY; DNA HISTONE INTERACTION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ERYTHEMA; EXTRAVASATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GENETIC ENGINEERING; GLIOBLASTOMA; GLIOMA; HEADACHE; HEMIPARESIS; HUMAN; LETHARGY; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHLEBITIS; POSTPRODECURE PAIN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SEIZURE; THROMBOCYTOPENIA; TUMOR LOCALIZATION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; GLIOMA; HUMANS; IMMUNOCONJUGATES; IODINE RADIOISOTOPES; NEOPLASM GRADING; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84863637447     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.58     Document Type: Review

References (43)

1. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J. Neurosurg. 95, 190-198 (2001).
2. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J. Neurosurg. 115, 3-8 (2011).
3. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence-guided resection of glioblastoma multiforme by using 5-Aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. J. Neurosurg. 93, 1003-1013 (2000).
4. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
5. Shirai K, Siedow MR, Chakravarti A. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J. Oncol. 2012, 193436 (2012).
6. Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
7. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
8. Kreisl TN, Kim L, Moore K et al. Phase II trial of single agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009).
9. Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142-148 (2011).
10. Ranpur V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: A meta-Analysis. JAMA 305(5), 487-494 (2011).
11. Zalutsky MR. Targeted radiotherapy of brain tumors. Br. J. Cancer 90, 1469-1473 (2004).
12. Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M. Anticancer antibodies. Am. J. Clin. Pathol. 119, 472-485 (2003).
13. Hudson PJ, Souriau C. Engineered antibodies. Nat. Med. 9, 129-134 (2003).
14. Goldsmith SJ, Signore A. An overview of the diagnostic and therapeutic use of monoclonal antibodies in medicine. QJ Nucl. Med. Mol. Imaging 54(6), 574-581 (2010).
15. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit. Rev. Oncol. Hematol. 54(1), 11-29 (2005).
16. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 348(6301), 552-554 (1990).
17. Reardon DA, Zalutsky MR, Bigner DD. Antitenascin C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer Ther. 7(5), 675-687 (2007).
18. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
19. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: The locoregional radioimmunotherapy approach. Eur. J. Nucl. Med. 27, 601-609 (2000).
20. Goetz C, Riva P, Poepperl G et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: E xperiences, side effects and survival times. J. Neurooncol. 62, 321-328 (2003).
21. Paganelli G, Bartolomei M, Ferrari M et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: PHASE I study and preliminary therapeutic results. Cancer Biother. Radiopharm. 16, 227-235 (2001).
22. Grana C, Chinol M, Robertson C et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br. J. Cancer 86, 207-212 (2002).
23. Bigner DD, Brown MT, Friedman AH et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: PHASE I trial results. J. Clin. Oncol. 16, 2202-2212 (1998).
24. Cokgor I, Akabani G, Kuan C-T et al. Phase I trial results of idodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 18, 3862-3872 (2000).
25. Reardon DA, Akabani G, Coleman RE et al. Phase II trial of murine 131I-labelled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20, 1389-1397 (2002).
26. Akabani G, Cokgor I, Coleman RE et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int. J. Radiat. Oncol. Biol. Phys. 46(4), 947-958 (2000).
27. Reardon DA, Quinn JA, Akabani G et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: PHASE I trial results. J. Nucl. Med. 47(6), 912-918 (2006).
28. Zalutsky MR, Reardon DA, Akabani G et al. Clinical experience with alpha-particle-emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med. 49(1), 30-38 (2008).
29. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 972-975 (2004).
30. Li L, Quang TS, Gracely EJ et al. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma. J. Neurosurg. 113, 192-198 (2010).
31. Casacó A, López G, García I et al. Phase I single-dose study of intracavitary-Administered nimotuzumab labeled with 188Re in adult recurrent high-grade glioma. Cancer Biol. Ther. 7(3), 333-339 (2008).
32. Waitz D, Putzer D, Kostron H, Virgolini IJ. Treatment of high-grade glioma with radiolabelled peptides. Methods 55(3), 223-229 (2011).
33. Schumacher T, Hofer S, Eichhorn K et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: An extended pilot study. Eur. J. Nucl. Med. Mol. Imaging 29(4), 486-493 (2002).
34. Kneifel S, Cordier D, Good S et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin. Cancer Res. 12(12), 3843-3850 (2006).
35. Cordier D, Forrer F, Bruchertseifer F et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2) 11]-substance P: A pilot trial. Eur. J. Nucl. Med. Mol. Imaging 37(7), 1335-1344 (2010).
36. Cordier D, Forrer F, Kneifel S et al. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P - results from a Phase I study. J. Neurooncol. 100(1), 129-136 (2010).
37. Patel SJ, Shapiro WR, Laske DW et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 56, 1243-1252 (2005).
38. Shapiro WR, Carpenter SP, Roberts K, Shan JS. 131I chTNT 1/B mAb: Tumor necrosis therapy for malignant astrocytic glioma. Expert Opin Biologic. Ther. 6, 539-545 (2006).
39. Gupta DK. Open-label, dose confirmation study of interstitial Cotara (131I chTNT 1/B mAb) for the treatment of glioblastoma multiforme (GBM) at first relapse. Presented at: CONGRESS of Neurological Surgeons 2011 Annual Meeting. Washington, DC, USA, 1-6 October 2011 (Poster 984).
40. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules into the brain. Proc. Natl Acad. Sci. USA 91, 2076-2080 (1994).
41. Groothuis DR, Ward S, Itskovich AC et al. Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J. Neurosurg. 90, 321-331 (1999).
42. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother. Radiopharm. 17(4), 359-370 (2002).
43. Street HH, Goris ML, Fisher GA et al. Phase I study of 131I-chimeric(ch)TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biol. Radiopharm. 21(3), 243-256 (2006).